Logo

Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

Share this

M&A

Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

Shots: 

  • Novartis acquires IFM Tre- in all stock transaction for $1.575B. IFM Tre to receive $310M upfront & $1.265B milestones from Novartis. The transaction is expected to close in Q2’19
  • The focus of the acquisition is to expand Novartis’ immunomodulatory portfolio with the addition of IFM Tre's one clinical (IFM-2427) and two preclinical programs of NLRP3 inhibitors targeting NLRP3 inflammasome to treat multiple metabolic- fibrotic- autoimmune- and neurological diseases
  • IFM-2427 is a clinical stage antagonist targeted for chronic inflammatory disorders- including gout- atherosclerosis and nonalcoholic steatohepatitis (NASH)

  Ref: IFM Therapeutics | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions